Zynerba Pharmaceuticals (NASDAQ:ZYNE) Upgraded to “Strong-Buy” by BidaskClub

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday, May 18th, BidAskClub reports.

A number of other research firms have also weighed in on ZYNE. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Roth Capital started coverage on shares of Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $11.00 price target on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective

... read more at: https://rocklandregister.com/2019/06/10/zynerba-pharmaceuticals-zyne-upgraded-to-strong-buy-at-bidaskclub.html